HK1218882A1 - 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法 - Google Patents

用於治疗神经退化疾病和其它疾病的组合治疗剂和方法 Download PDF

Info

Publication number
HK1218882A1
HK1218882A1 HK16106972.1A HK16106972A HK1218882A1 HK 1218882 A1 HK1218882 A1 HK 1218882A1 HK 16106972 A HK16106972 A HK 16106972A HK 1218882 A1 HK1218882 A1 HK 1218882A1
Authority
HK
Hong Kong
Prior art keywords
bryoid
retinoid
effective amount
article
bryostatin
Prior art date
Application number
HK16106972.1A
Other languages
English (en)
Chinese (zh)
Inventor
Trevor Percival CASTOR
Original Assignee
Aphios Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphios Corporation filed Critical Aphios Corporation
Publication of HK1218882A1 publication Critical patent/HK1218882A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106972.1A 2012-11-28 2013-11-26 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法 HK1218882A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730761P 2012-11-28 2012-11-28
US61/730761 2012-11-28
PCT/US2013/072076 WO2014085494A1 (en) 2012-11-28 2013-11-26 Combination therapeutics and methods for the treatment of neurodegenerative and other diseases

Publications (1)

Publication Number Publication Date
HK1218882A1 true HK1218882A1 (zh) 2017-03-17

Family

ID=50828429

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106972.1A HK1218882A1 (zh) 2012-11-28 2013-11-26 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法

Country Status (6)

Country Link
US (1) US10828276B2 (enExample)
EP (1) EP2925314B1 (enExample)
JP (1) JP6579956B2 (enExample)
CN (1) CN105228614A (enExample)
HK (1) HK1218882A1 (enExample)
WO (1) WO2014085494A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
JP6579956B2 (ja) 2012-11-28 2019-09-25 アフィオス コーポレーション 神経変性疾患および他の疾患の治療のための併用治療薬および方法
WO2026024784A1 (en) * 2024-07-22 2026-01-29 Mastery Biotech Co., Ltd. Composition and method for preventing or treating neurodegenerative diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5440055A (en) 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5854064A (en) 1996-07-31 1998-12-29 Aphios Corporation Methods for fractionation of biologically-derived materials
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
EP0888458A4 (en) 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6228843B1 (en) 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
CA2393026A1 (en) 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US20080004332A1 (en) 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
CA2490494A1 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds
JP4890759B2 (ja) 2002-07-02 2012-03-07 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート ｓＡＰＰα分泌を増強させる及びブリオスタチン型化合物を用いて認知を改善させるための手段としてのＰＫＣ活性化
US8088605B2 (en) * 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7871358B2 (en) * 2005-10-14 2011-01-18 Gary Graham Height adjustable shuttle treatment table/exercise device method and apparatus
WO2007114881A1 (en) 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
CN101848726A (zh) 2007-02-09 2010-09-29 布朗歇特洛克菲勒神经科学研究所 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US8497385B2 (en) * 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US20100168219A1 (en) 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US20120309818A1 (en) 2007-12-31 2012-12-06 Jonathan Steven Alexander Chronic inflammation and transplantation
WO2009129361A2 (en) 2008-04-16 2009-10-22 University Of Utah Research Foundation Macrocyclic compounds and methods of making and using thereof
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20110129450A1 (en) * 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
US20100166806A1 (en) * 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
CN102459180B (zh) * 2009-06-09 2014-05-14 江苏迈度药物研发有限公司 作为激酶抑制剂的脲衍生物
WO2013071282A1 (en) * 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
CN105008342B (zh) 2012-11-27 2018-10-19 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
JP6579956B2 (ja) 2012-11-28 2019-09-25 アフィオス コーポレーション 神経変性疾患および他の疾患の治療のための併用治療薬および方法

Also Published As

Publication number Publication date
WO2014085494A1 (en) 2014-06-05
JP2016501225A (ja) 2016-01-18
WO2014085494A8 (en) 2015-04-23
EP2925314B1 (en) 2020-04-01
US10828276B2 (en) 2020-11-10
CN105228614A (zh) 2016-01-06
EP2925314A1 (en) 2015-10-07
US20150297555A1 (en) 2015-10-22
JP6579956B2 (ja) 2019-09-25
EP2925314A4 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
US10485766B2 (en) Drug delivery system and method for the treatment of neuro-degenerative disease
KR20080058326A (ko) 나노에멀젼 조성물 및 이의 제조 및 사용 방법
AU2022202308A1 (en) Ubiquinone and ubiquinol compositions, and methods relating thereto
CN114796110A (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
US10828276B2 (en) Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
AU2019203815A1 (en) Oral Composition of Celecoxib For Treatment of Pain
CN110200833A (zh) 一种根皮素纳米乳制剂及其制备方法和应用
US20210030678A1 (en) Cannabinoid and cbd liposome formulations and uses thereof
EP3352735B1 (en) Sustained release olanzapine formulations
US20220142934A1 (en) Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
KR102108153B1 (ko) 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물
CN1698620B (zh) 一种可过滤除菌的葫芦素乳剂及制备方法
EP3883547B1 (en) Preparation and use of cannabis nano-formulation
CN111407725B (zh) 一种拉莫三嗪乳剂及其制备方法
CN109200018A (zh) 含有奈妥吡坦的微乳制剂
RU2817530C1 (ru) Получение и применение наносостава конопли
CN110115766B (zh) 一种含有氟比洛芬酯的复方制剂及其制备方法
WO2020008359A1 (en) A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases
CN100560058C (zh) 一种口服、快速起效的镇痛药物
CN115804753A (zh) 阿戈美拉汀自微乳组合物、胶囊剂及其应用
BRAHIMI et al. Indian Journal of Novel Drug Delivery
CN113827562A (zh) 用于口服和胃肠外给药的稳定的氯吡格雷游离碱药物组合物
HK1255946B (en) Sustained release olanzapine formulations
CN102552286A (zh) 糠酸莫米松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物
CN102475708A (zh) 丙酸氟替卡松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物